Journal of the International AIDS Society
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
Inhaltsverzeichnis
-
Journal of the International AIDS Society: an important step forwardWainberg, Mark A / Katabira, Elly / Heidari, Shirin et al. | 2008
-
Benefits of an educational program for journalists on media coverage of HIV/AIDS in developing countriesMartinez-Cajas, Jorge L / Invernizzi, Cédric F / Ntemgwa, Michel et al. | 2008
-
HIV/AIDS, conflict and security in Africa: rethinking relationshipsBecker, Joseph U / Theodosis, Christian / Kulkarni, Rick et al. | 2008
-
Prevention of the sexual transmission of HIV-1: preparing for successCohen, Myron S / Kaleebu, Pontiano / Coates, Thomas et al. | 2008
-
HIV prevention: What have we learned from community experiences in concentrated epidemics?Spire, Bruno / de Zoysa, Isabelle / Himmich, Hakima et al. | 2008
-
Confronting TB/HIV in the era of increasing anti-TB drug resistanceChakaya, Jeremiah / Getahun, Haileyesus / Granich, Reuben et al. | 2008
-
HIV is a virus, not a crime: ten reasons against criminal statutes and criminal prosecutionsCameron, Edwin / Burris, Scott / Clayton, Michaela et al. | 2008
-
Fear of Foreigners: HIV-related restrictions on entry, stay, and residenceAmon, Joseph J / Todrys, Katherine Wiltenburg et al. | 2008
-
Sex between men in the context of HIV: The AIDS 2008 Jonathan Mann Memorial Lecture in health and human rightsSaavedra, Jorge / Izazola-Licea, Jose Antonio / Beyrer, Chris et al. | 2008
-
O314 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study groupPetoumenos, K / Fontas, E / Worm, SW et al. | 2008
-
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirineNozza, S / Visco, F / Soria, A et al. | 2008
-
Different metabolic and anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: Results from the "NEVIRAPINE COMPANION" cohortGuaraldi, G / Adorni, F / Zona, S et al. | 2008
-
Transient therapy with quadruple NRTI provides immune stability in patients with multidrug resistant HIV-1 and no options for suppressive regimensBonjoch, A / Llibre, JM / Negredo, E et al. | 2008
-
O324 HIV, immune deficiency and malignancyGrulich, AE et al. | 2008
-
Patient-reported outcomes after simplification to a single tablet regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir DF (TDF)Hodder, S / Mounzer, K / DeJesus, E et al. | 2008
-
Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week resultsMallolas, J / Podzamczer, D / Domingo, P et al. | 2008
-
O333 Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART)Smith, CJ / Lampe, FC / Youle, M et al. | 2008
-
O411 HIV-TB co-infection and TB drug resistance: an emerging threat to HIV and TB programmesFriedland, GH et al. | 2008
-
Once-daily saquinavir (SAQ)/ritonavir (RTV) (2000/100 mg) with abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/300 mg) in naïve patientsBickel, M / Bodtlaender, A / Knecht, G et al. | 2008
-
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)Absalon, J / Thal, G / Thiry, A et al. | 2008
-
Efficacy and safety of tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected patients in clinical setting. The TEAL studyEccleston, KJ / Bambumba, A / Babu, CS et al. | 2008
-
Good experience of enfurvitide in severely ill patientsGyllensten, K / Granholm, H / Blaxhult, A et al. | 2008
-
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patientsCamanni, G / Toraldo, G / Rosignoli, D et al. | 2008
-
Adherence with lopinavir/ritonavir (LPV/r) tablet and SoftGel (SGC) capsule based antiretroviral regimens and predictors of early treatment compliancePodsadecki, TJ / Rode, RA / Naylor, C et al. | 2008
-
Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT)Ayoub, A / Goodrich, J / Tressler, R et al. | 2008
-
Peri-renal fat diameter is related to intima media thickness and renal arterial resistance index in HIV-1 infected patientsGrima, PF / Chiavaroli, R / Grima, P et al. | 2008
-
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studiesFätkenheuer, G / Clotet, B / Pialoux, G et al. | 2008
-
Frequency of functional drug disposition gene polymorphism in Thai population: relevance to antiretroviral drugsChaikan, A / Chierakul, N / Saguenwong, N et al. | 2008
-
Tenofovir toxicity in children: two clinical casesBengleil, AS / Kambraki, M / Al Fituri, O et al. | 2008
-
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samplesSantos, JR / Llibre, JM / Pérez-Álvarez, N et al. | 2008
-
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjectsNg, J / Klein, CE / Chui, YL et al. | 2008
-
Evaluation of Roche Cobas Taqman Quantitative HIV-1 RNA PCR against other HIV-1 commercial viral load tests to examine potential under-quantificationCouto-Parada, X / Lee, A / Ushiro-Lumb, I et al. | 2008
-
Managing HIV in pregnancy in GlasgowPatton, V / Fox, R / Nandwani, R et al. | 2008
-
Once-daily darunavir (DRV) used in routine clinical care produces trough DRV drug concentrations in excess of 30× the protein-corrected (PC) $ EC_{50} $for wild-type HIVRobertson, CM / Jayasuriya, AN / Smith, CJ et al. | 2008
-
Immune and virologic responses to Truvada or Combivir as a first-line therapy of HIV-infected, treatment-naïve patientsMaserati, R / Clerici, M / Lauriola, M et al. | 2008
-
Clinical mentoring: a sustainable strategy for scaling up HIV/AIDS clinical expertise in developing countriesAggett, S / Shantz, K / Mair, R et al. | 2008
-
Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similarTeppler, H / Rockstroh, J / Isaacs, R et al. | 2008
-
The use of enfuvirtide-based HAART regimens in HIV patients undergoing chemotherapy for lymphomaWhite, BA / Fox, R / Laird, J et al. | 2008
-
Cost-minimisation analysis of the use of etravirine or raltegravir in treatment-experienced HIV-1-infected patientsMartin, S / Smets, E et al. | 2008
-
Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapyPett, SL / Zaunders, J / Bailey, M et al. | 2008
-
Do cerebral function test results correlate when measured by a computerised battery test and a memory questionnaire in HIV-1 infected subjects?Garvey, LJ / Yerrakalva, D / Winston, A et al. | 2008
-
Treatment outcome of chronic hepatitis C in HIV-infected patients at the Institute of Tropical Medicine, Antwerp, Belgium, from 2000 to 2008Bottieau, E / Florence, E / De Boer, M et al. | 2008
-
Comparison of the efficacy at 48 weeks of first-line antiretroviral treatment for HIV infection in 1998 and 2006: a multicentric investigationSozio, F / Soddu, V / De Socio, G et al. | 2008
-
O322 Bone disease and HIV – together for the long termMallon, P et al. | 2008
-
Switching from enfuvirtide to etravirine – efficacy results from the etravirine expanded access programmeRibera, E / Florence, E / De Wit, S et al. | 2008
-
Substitution of nevirapine for efavirenz in virologically controlled patients intolerant of efavirenzWard, DJ / Curtin, JM / Miller, EJ et al. | 2008
-
3OD – Once-daily (OD) TDF-containing HAART in HIV-1-infected former IVDU-patients receiving opiate substitution: efficacy, tolerability and adherenceEsser, S / Staszewski, S / Haberl, AE et al. | 2008
-
Effect of age on response to and tolerability of highly active antiretroviral therapy: a case-control studyFrancisci, D / Masini, G / Papili, R et al. | 2008
-
Assessment for sonographic grading scales of the body fat changes related to the lipoatrophic findings of HIV patients in treatment with HAARTGulizia, R / Gervasoni, C / Ortu, M et al. | 2008
-
Highly active antiretroviral treatment (HAART) interruption leads to an increase in mitochondrial DNA content in HIV-infected childrenMorén, C / Garrabou, G / Rovira, N et al. | 2008
-
Clinical concentrations of efavirenz (EFV) reduce cellular proliferation and viability in several human cell linesApostolova, N / Blas-García, A / Ballesteros, D et al. | 2008
-
HIV patients' gastrointestinal tolerability and treatment satisfaction after switching from lopinavir/ritonavir (LPV/r) SGC to co-formulated LPV/r tabletsBorras-Blasco, J / Rosique-Robles, JD / Belda, A et al. | 2008
-
Correlates of spinal deforming index (SDI) in HIV-positive patients naive and on treatmentCasana, M / Bini, T / Cicconi, P et al. | 2008
-
Kidney tubular abnormalities in HIV patients treated with tenofovir with normal glomerular function – results of a prospective study on 284 patientsLabarga, P / Barreiro, P / Martin-Carbonero, L et al. | 2008
-
A cross-sectional comparison of renal function in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapyWaters, LJ / Randell, P / Jackson, AGA et al. | 2008
-
Study of HIV-positive patients with asymptomatic retroperitoneal lymphadenopathy on antiretroviral therapy for the development of IRISTripathi, AK / Gupta, N / Khanna, M et al. | 2008
-
Is HAART based on newest active antiretroviral drugs influenced by GSS?Ortu, MO / Vitiello, PV / Adorni, FA et al. | 2008
-
Are non-B subtypes less susceptible to antiretroviral drugs? A bioinformatical approach to prediction of non-B subtype susceptibilityKjær, J / Høj, L / Cozzi-Lepri, A et al. | 2008
-
Therapeutic drug monitoring of atazanavir in pregnancyLambert, J / Else, LJ / Jackson, V et al. | 2008
-
Characteristics distinguishing disseminated Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infection in HIV patientsBailey, AC / Samarawickrama, A / Ibrahim, F et al. | 2008
-
An open-label multicentre pilot study evaluating the pharmacokinetics (PK) of co-administered lopinavir (LPV) and nevirapine (NVP) in HIV+ adultsElse, LJ / Mahungu, TW / Cuthbertson, Z et al. | 2008
-
Impact of CMV infection on horizontally transmitted HIV-1 disease progressionCupsa, A / Dumitrescu, F / Giubelan, L et al. | 2008
-
Rapid rebound in hepatitis B DNA in previously undetectable hepatitis B/HIV co-infected patients switching from tenofovir to entecavir therapyHull, M / Toy, J / Montessori, V et al. | 2008
-
A cost-effectiveness analysis of Maraviroc in treatment-experienced HIV patients in ScotlandLekander, I / Berg, J / Christie, A et al. | 2008
-
Varicella vaccination in HIV-positive individuals – a time to actde Barra, E / Rock, C / Kiely, B et al. | 2008
-
O131 Where are we with National and International guidelines?Katabira, E et al. | 2008
-
Efficacy of shorter duration HCV treatment in injection drug users (IDUs)Barrieshee, A / Conway, B et al. | 2008
-
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204Molina, JM / Cordes, C / Ive, P et al. | 2008
-
Age-related co-morbidities in people living with HIVGuaraldi, G / Zona, S / Orlando, G et al. | 2008
-
Nevirapine (NVP), tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) is effective and well tolerated in naïve HIV-1 infected patientsBickel, M / Gute, P / Carlebach, A et al. | 2008
-
Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profileBlanco, F / Arredondo, M / Guevara, F et al. | 2008
-
O223 Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reportsBeckerman, KP / Covington, D / Dominguez, K et al. | 2008
-
Cost-effectiveness of switching to second-line therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for UgandaSimpson, KN / Dietz, B / Rahim, SX et al. | 2008
-
O231 Cryptogenetic liver disease, steatosis, portal hypertension, transaminitis and antiretroviralsPol, S et al. | 2008
-
Raltegravir therapy in HIV multi-experience patients: safety and efficacyMeraviglia, P / Capetti, A / Merli, S et al. | 2008
-
Positive predictive factors in HIV-1 patients treated with enfuvirtide plus an OB that include an active boosted PI. Preliminary FastFuz study resultsRibera, E / Antela, A / Henarejos, JA Garcia et al. | 2008
-
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patientsDe Meyer, S / Lathouwers, E / Dierynck, I et al. | 2008
-
O425 Efficacy and safety of maraviroc in treatment-experienced (TE) patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studiesHardy, WD / Gulick, R / Mayer, HB et al. | 2008
-
Antiretroviral treatment efficacy after mutations reversion during T20 monotherapy, an alternative strategy in multi-failed HIV-1 infected patientsLo Caputo, S / Santoro, M / Ceccherini-Silberstein, CSF et al. | 2008
-
Abacavir/lamivudine has shown similar efficacy to other nucleoside conventional combinations in previously HIV-infected patients: results at 48 weeksEcheverría, P / De la Torre, J / Pasquau, J et al. | 2008
-
Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programmeFlorence, E / De Wit, S / Castagna, A et al. | 2008
-
FREE trial: induction therapy with ART (abacavir/lamivudine/lopinavir/r) followed by maintenance regimen with triple NRTI, compared to continued ARTSprenger, HG / ten Napel, CHH / Vriesendorp, R et al. | 2008
-
Comparative assessment of coronary risk in HIV-infected patient cohort using Framingham index and Spanish validated coronary risk index: REGICORJiménez, M Cervero / Perea, R Torres / Aparicio, JL Agud et al. | 2008
-
Impairment of functional integrity of the vasculature is not changed in patients starting abacavirZona, S / Lattanzi, A / Squillace, N et al. | 2008
-
Mitochondrial toxicity of antiretrovirals in non-HIV-infected patientsGarrabou, G / Pedrol, E / Deig, E et al. | 2008
-
Factors correlated to non-adherence to antiretroviral therapy among immigrants from poor resource countries, attending a reference center in RomePierro, P / Lorenzini, P / Trotta, MP et al. | 2008
-
An audit of cardiovascular disease risk management in HIV-infected patients attending a northern English hospitalBuxton, GL / Chadwick, DR et al. | 2008
-
Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH CohortTeira, R / Geijo, P / Cosín, J et al. | 2008
-
Etravirine protects the activity of darunavir in the DUET trialsPeeters, M / Vingerhoets, J / Tambuyzer, L et al. | 2008
-
Peripheral blood CD4+ T-lymphocyte count influences cerebrospinal fluid cellular response in patients with HIV-related cryptococcal meningitisCecchini, DM / Cañizal, AM / Rojas, H et al. | 2008
-
Switching from zidovudine/lamivudine (ZDV/LMV) to tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/LMV) in HIV/HCV co-infection (COTKI study)Nasta, P / Gatti, F / Matti, A et al. | 2008
-
23% of newly diagnosed HIV cases in 2007 at Karolinska University Hospital had opportunistic infectionsEgnell, K / Svedhem, V et al. | 2008
-
HCV relapse after peg-interferon (IFN) plus ribavirin (RBV) therapy: is 12-week follow-up enough to determine sustained HCV clearance?Medrano, J / Resino, S / Vispo, E et al. | 2008
-
Frequency of hepatic steatosis in HIV and hepatitis C co-infected patients treated by antiretroviral therapy during 1995 to 2008Martinez, V / Dieu TA, N Thi / Guiget, M et al. | 2008
-
Evaluating affordable screening markers to detect HIV-1-infected Ugandan adults with CD4 counts of less than 200 cells/mulMiiro, GM / Todd, J / Nakubulwa, S et al. | 2008
-
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice – 2-year data from the German Outpatient Cohortvan Lunzen, J / Fätkenheuer, G / Lutz, T et al. | 2008
-
GBV-C/HIV co-infected patients from AIDS Center Prague have higher CD4 cell counts and probably better quality of lifeAster, V / Konig, J / Rozsypal, H et al. | 2008
-
Comparing the efficacy of $ Truvada^{®} $ and $ Kivexa^{®} $ combination therapy in HAART-naive individuals with different viral loadsDaniels, RH / Gazzard, BG / Holmes, P et al. | 2008
-
HCV genotypes distribution in the Nizhny Novgorod area HIV-positive populationMinaeva, S / Moshkovich, G / Tikhonova, E et al. | 2008
-
Perceptions of obesity amongst a mixed HIV cohort in London, UK – Slim is no longer SlimBradbeer, CS / Bakar, MS Abu et al. | 2008
-
O115 Importance of detecting minority variants in the clinical management of HIVKuritzkes, D et al. | 2008
-
O221 Optimising paediatric treatment for long term survival. Adult survivors of congenital HIV infection – what problems will they have?Lyall, H et al. | 2008
-
INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patientsReynes, J / Pellegrin, I / Peytavin, G et al. | 2008
-
Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutationsLlibre, JM / Domingo, P / Blanco, F et al. | 2008
-
L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)Vachta, J / Wiesmann, F / Braun, P et al. | 2008
-
O321 Management of renal disease in HIV infection for the HIV physicianWilliams, I et al. | 2008
-
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapiesRodriguez-Arrondo, F / Aguirrebengoa, K / Portu, J et al. | 2008
-
O331 Patterns of viral suppression on cART as predictors of uncontrolled viremia after starting a new antiretroviral after 1 January 2003Reekie, J / Mocroft, A / Ledergerber, B et al. | 2008
-
48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trialRibera, E / Clotet, B / Martínez, E et al. | 2008
-
Management of antiretroviral therapy (ART) in AlbaniaHarxhi, A / Kraja, D / Shehu, E et al. | 2008
-
HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapyBoothby, M / Umpleby, AM / Shojaee-Moradie, F et al. | 2008
-
Statistical agreement between ultrasound (US) and computerized tomography (CT) for non-alcoholic liver disease (NAFLD) diagnosisZona, S / Ballestri, S / Lonardo, A et al. | 2008
-
Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status?Rubio, R / Johnson, MA / Haas, BJ et al. | 2008
-
Mitochondrial effects of 3 years of CD4-guided HIV treatment interruptionGarrabou, G / Negredo, E / Morén, C et al. | 2008
-
Sensory neuropathy not associated with interruption of ARV therapy in taking stavudine-lamivudine-nevirapine combination HAART in Abuja, NigeriaSalami, O / Ghaji, N / Awunor, C et al. | 2008
-
Dispositional optimism, perceived health competence and adherence in highly antiretroviral-experienced patientsFumaz, CR / Muñoz-Moreno, JA / Ferrer, MJ et al. | 2008
-
CNA110329: a prospective epidemiological study to determine the prevalence of HLA-B*5701 in HIV-1 infected individuals in five European countriesPrins, JM / Rauch, A / Bergin, C et al. | 2008
-
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxoneBruce, RD / Altice, FL / Moody, DE et al. | 2008
-
Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL studyDickinson, L / Boffito, M / Else, LJ et al. | 2008
-
Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5Trinh, L / Han, D / Huang, W et al. | 2008
-
Elite controllers or misquantification of virus load by Cobas TaqMan?Taylor, N / Jauer, M / Bijuklic, K et al. | 2008
-
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulationNg, J / Klein, CE / Diderichsen, P et al. | 2008
-
Estimating renal impairment and evaluating antiretroviral dose adjustments among HIV-positive patients: a comparison of three hospitalsMackie, K / Weston, R / Sonecha, S et al. | 2008
-
Prevalence and risk factors associated with loss to follow-up in a cohort of HIV-infected patients treated with highly active antiretroviral treatmentMorreel, S / Schepens, T / Florence, E et al. | 2008
-
Absence of liver steatosis in HIV-infected patients receiving tenofovir-containing regimenBorghi, V / Mussini, C / Manzini, L et al. | 2008
-
O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patientsKityo, C / Walker, AS / Lutwana, F et al. | 2008
-
O132 Secondline ART in the developing worldHakim, J et al. | 2008
-
Experience with ritonavir/atazanavir in HIV-positive antiretroviral-naïve individuals commencing therapyGraf, B / Taylor, K / Gupta, A et al. | 2008
-
HAART in HIV+ naive elderly patients: immuno-virological response and clinical outcomeCelesia, BM / Bisicchia, F / La Rosa, R et al. | 2008
-
Effects of NRTI backbone on HIV RNA, CD4 counts and lipids for first-line boosted PI-based HAART: meta-analysis of 12 clinical trials in 4,896 patientsHill, AM / Sawyer, WA et al. | 2008
-
Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE studyUy, J / Yang, R / Thiry, A et al. | 2008
-
O232 What's new in hepatitis C?Soriano, V et al. | 2008
-
O233 Surrogate markers for liver damage (i.e. how can we measure the extent of fibrosis and disease without biopsy)Puoti, M et al. | 2008
-
Darunavir in patients who failed on fos-amprenavir: efficacy at week 48De Wit, S / Delforge, M / Kabeya, K et al. | 2008
-
Efficacy, safety and tolerability of enfuvirtide in a population of Portuguese HIV-1 chronically infected patientsMiranda, AC / Almeida, I / Mendez, J et al. | 2008
-
Virological treatment outcome under HAART: does sex matter?Haberl, AE / Usadel, S / Hanhoff, N et al. | 2008
-
Real-life effectiveness and safety of lopinavir/ritonavir in HIV-infected adults who experienced prior different antiretroviral treatmentsConway, B / DeWet, J / Tsang, A et al. | 2008
-
Carotid intima media thickness with no cardiovascular disease in HIV-infected patients correlates with a hyperactivated/pro-apoptotic T-cell phenotypeTincati, C / Bellistrì, GM / Casana, M et al. | 2008
-
Neurotoxic effect of antiretroviral agents on CNSHusstedt, IW / Reichelt, D / Oelker-Grueneberg, U et al. | 2008
-
A 24-month follow-up of the metabolic profile of Greek HIV (+) population on lopinavir/ritonavir-based regimen: the ACA GREC trialMetallidis, SM / Lazanas, ML / Gargalianos, PG et al. | 2008
-
Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study)Maggiolo, F / Airoldi, M / Trotta, MP et al. | 2008
-
Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophyGuaraldi, G / Zona, S / D'Amico, R et al. | 2008
-
Sticky platelet syndrome (SPS) in patients with AIDS: a cross-sectional studyLopez, H Castro / Cisneros, L Nieto / Perez, S Trevino et al. | 2008
-
Adherence to antiretroviral therapy among children receiving therapy in a resource-poor settingBisimba, JE / Naubutu, JP / Swai, E et al. | 2008
-
Adherence, coping strategies and depression in highly antiretroviral-experienced patientsFumaz, CR / Muñoz-Moreno, JA / Ferrer, MJ et al. | 2008
-
Health-related quality of life in HIV-infected patients in a private practice in GermanyMauss, S / Henke, J / Berger, F et al. | 2008
-
Reduced susceptibility to lamivudine and emtricitabine associated with the novel K66N mutation in HIV-1 reverse transcriptaseVerlinden, Y / Muyldermans, G / Van Houtte, M et al. | 2008
-
Incidence of the resistance mutation K65R on reverse transcriptase in different HIV-1 subtypesTurner, D / Pollack, S / Kachman, E et al. | 2008
-
D-dimer and anti-coagulation activity markers in children and adolescents with HIV infectionPontrelli, G / Tchidjou, H / Citton, R et al. | 2008
-
Genotypic susceptibility to tipranavir of HIV-1 isolates in treatment-experienced patientsPiliero, P / Bhatti, L / Coakley, E et al. | 2008
-
Impact on bone mineral density of tenofovir-containing HAART in HIV-1 infected children and adolescents: a report from 5 years of clinical experienceRosso, R / Di Biagio, A / Parodi, A et al. | 2008
-
Lopinavir is a substrate for SLCO1A2 but 516A>C and 38T>C polymorphisms do not influence lopinavir plasma concentrationsShallcross, V / Kwan, WS / Hartkoorn, R et al. | 2008
-
The pharmacokinetic (PK) interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)Crauwels, HM / van Heeswijk, RPG / Kestens, D et al. | 2008
-
Impact of HIV viral diversity and baseline resistance on treatment outcomes and the emergence of resistance: the CASTLE study 48-week resultsLataillade, M / Yang, R / Mancini, MD et al. | 2008
-
Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patientsAvihingsanon, A / van der Lugt, J / Kerr, S et al. | 2008
-
Influence of gender in predicting CCR5 coreceptor usageNozza, S / Soria, A / Visco, F et al. | 2008
-
Reproducibility of a high-throughput HIV-1 genotypic resistance assay over time (2001–2007)Deloof, A / Muyldermans, G / Pattery, T et al. | 2008
-
Cross-sectional study to determine prevalence of significant liver fibrosis (F2–F4) in HIV/HCV co-infected patients: GRAFIHCO studyTural, C / Ortega, E / Pineda, JA et al. | 2008
-
Patient satisfaction survey for the home delivery of medication schemeSmith, B / Sonecha, S / Murungi, A et al. | 2008
-
Analysis of viral load, CD4+ and CD8+ T-cell from HIV-1 infected patients enrolled in the AIDS programs from the city of Santos, BrazilZetehaku, AC / Lins-Filho, AFP / Rabelato, JT et al. | 2008
-
Predictors of immune reconstitution inflammatory syndrome associated with Kaposi sarcoma (IRIS-KS) in a rural area of MozambiqueLetang, E / Almeida, J / Ayala, E et al. | 2008
-
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in SpainNieves, D / de la Calle, O / Iribarren, JA et al. | 2008
-
Cost consequences of HIV-associated lipoatrophyHornberger, J / Rajagopalan, R / Shewade, A et al. | 2008
-
The Rainbow Cohort: saquinavir/r is effective and well tolerated in antiretroviral therapy (ART)-naïve patients – 48-week results from GermanyKnechten, H / Stephan, C / Lutz, T et al. | 2008
-
Substitution of tenofovir for nucleoside analogues in virologically controlled HIV-infected patients co-infected with hepatitis C virus: TEN-SWITCHGrebely, J / Gallagher, L / Knight, E et al. | 2008
-
O135 Seek and treat for optimal prevention of HIV/AIDS (STOP HIV/AIDS)Montaner, JSG et al. | 2008
-
O111 Global impact of HIV drug resistancePillay, D et al. | 2008
-
Sexual dysfunction in HIV-infected women: prevalence and related factorsGuelar, AM / Villar, J / Sorlí, ML et al. | 2008
-
Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trialsClumeck, N / Clotet, B / Johnson, MA et al. | 2008
-
O121 Drug interactions that really matterKhoo, SH et al. | 2008
-
Similar virological response rates for ART-naïve subjects starting KVX + LPV/r or TVD+ LPV/r. Data from the prospective observational STAR cohortWolf, E / Trein, A / Schmidt, W et al. | 2008
-
POWER 3 analysis: 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patientsPozniak, A / Arastéh, K / Molina, JM et al. | 2008
-
Cost-effectiveness of tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults with HIV infection in the USABrogan, AJ / Everhard, F / Talbird, SE et al. | 2008
-
Tipranavir in highly ARV-experienced patients: efficacy and tolerability results from the French prospective NADIS cohortAllavena, C / Flandre, P / Pugliese, P et al. | 2008
-
Efficacy and tolerance of combination of maraviroc with MK-0518, boosted TMC-114, TMC-125, in heavily pre-treated CCR5-positive patientsAlmasi, F / Krivine, A / Compangocci, A et al. | 2008
-
Darunavir exhibits a potent activity as boosted PI in subjects on a salvage antiretroviral regimenVitiello, P / Ferramosca, S / Lo Cicero, M et al. | 2008
-
O412 Factors associated with poor clinical outcome among HIV-infected patients with tuberculosis (TB) in Europe and Argentina. The HIV/TB collaborative studyPodlekareva, D / Mocroft, A / Post, FA et al. | 2008
-
Use of lopinavir/ritonavir in first-line therapy or second-line therapy: 48-week results from the German prospective STAR cohortKoegl, C / Trein, A / Schmidt, W et al. | 2008
-
Unexplained severe portal hypertension in HIV-infected patients: a new clinical entity?Maida, I / Vispo, E / Sotgiu, G et al. | 2008
-
HIV and antioxidant lipoprotein-associated effect. Is there a correlation?Pereira, SA / Batuca, J / Caixas, U et al. | 2008
-
Quantitative and qualitative mtDNA-lesions with mitochondrial dysfunction in multiple organs after HAART-associated fatal lactacidosisThoden, J / Lebrecht, D / Venhoff, N et al. | 2008
-
Do genetic polymorphisms associated with inflammation/lipodystrophy or endothelial damage predict carotid alterations in HIV+ subjects under cART?Donati, K de Gaetano / Rossi, M / Iannotti, N et al. | 2008
-
Hypertension is the most common component of the metabolic syndrome in a cohort of NRTI-based HAART treated patients – a preliminary reportIwuala, SO et al. | 2008
-
Evaluation of kidney toxicity in HIV patients with tenofovir-based regimen: the role of boosted protease inhibitor in real clinical settingOrtu, F / Piano, P / Serra, P et al. | 2008
-
Loss to follow-up in HIV immigrant patients. Is it a relevant problem? Results of the Spanish COMESEM cohortCervero, M / Torres, R / Aparicio, JL Agud et al. | 2008
-
Depression in HIV patients is associated with low adherence: a cross-sectional study among HIV patients in DenmarkRodkjaer, LO / Laursen, T / Balle, N et al. | 2008
-
Metabolic evaluation of Study M05-730: LPV/r tablets QD vs. BID, co-administered with tenofovir DF + emtricitabine in ARV-naïve HIV-1 infected subjectsDa Silva, BA / Cohen, DE / Marsh, TM et al. | 2008
-
cART in vertically HIV-infected children treated since infancyMarczyñska, M / Oldakowska, A / Dobosz, S et al. | 2008
-
Regular audit can lead to changes in practice and better outcomes for pregnant women with HIVPatton, V / Fox, R / Nandwani, R et al. | 2008
-
Impact of the HIV-1 protease N88S substitution on protease inhibitor susceptibility and clinical responseUy, J / Lataillade, M / Thiry, A et al. | 2008
-
Is prognosis after first AIDS-defining pathology incidence becoming better in recent years of HAART era?Gaspar, G / Melero, JA / Contés, E et al. | 2008
-
Impact of highly active antiretroviral therapy on cytomegalovirus viraemia, in the absence of specific anti-cytomegalovirus therapyMihailescu, R / Paraschiv, S / Arama, V et al. | 2008
-
Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reductionGiola, M / Cusato, M / Villani, P et al. | 2008
-
Acute hepatitis C infection in a cohort of HIV-infected patients in BelgiumFlorence, E / Bottieau, E / Boer, M Van Den et al. | 2008
-
Cost-effectiveness of DRV/r 600/100 mg BID in treatment-experienced, LPV/r-naïve, PI-resistant, HIV-infected adults in the UK, Belgium, Italy and SwedenMoeremans, K / Hemmett, LC / Hjelmgren, J et al. | 2008
-
Impact of hyperglycemia and cholesterol levels on the outcome of hepatitis C treatment in HIV/HCV co-infected patientsCesari, M / Caramma, I / Antinori, S et al. | 2008
-
Hospital admissions and associated diagnosis of HIV patients in the HAART eraPrisca, A / Caldas, C / Xerinda, S et al. | 2008
-
How will we use the new ART drugs?Katlama, C et al. | 2008
-
O213 CD4-guided STI in patients responding to HAARTMaggiolo, F / Airoldi, M / Callegaro, A et al. | 2008
-
O224 The early AIDS epidemic in the U.S.: views from Atlanta and HollywoodJaffe, H et al. | 2008
-
O122 Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, KenyaKigen, GK / Kimaiyo, S / Back, DJ et al. | 2008
-
Patient retention on antiretroviral therapy programme: risk factor analysis of a Uganda cohortMills, EJ / Olupot-Olupot, P / Cooper, C et al. | 2008
-
O312 Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factorsLundgren, JD et al. | 2008
-
O423 Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohortZoufaly, A / Kreuzberg, C / An der Heiden, M et al. | 2008
-
Induction strategy with enfuvirtide: results from the Fuziona study, a multicenter retrospective study in SpainMora, M / Navarro, C / Gonzalez-Mena, A et al. | 2008
-
O332 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patientsBannister, WP / Mocroft, A / Kirk, O et al. | 2008
-
Efficacy and safety of ritonavir-boosted fosamprenavir (FPV/r) in HIV-infected patients: 48-week results from an observational studyHain, JF / Eberle, S / Walli, RK et al. | 2008
-
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of the metabolic syndromeBlanco, F / Barreiro, P / Ryan, P et al. | 2008
-
Long-term satisfaction and benefits on quality of life in HIV-infected people after reparatory treatment with $ Aquamid^{®} $for facial LipoatrophyMuñoz-Moreno, JA / Puig, J / Fumaz, CR et al. | 2008
-
KAPITAL2: a study of treatment satisfaction reported by patients on lopinavir/r anchored regimens and physicians who provide HIV careCasado, JL / Griffa, L / Cabrero, E et al. | 2008
-
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patientsStentarelli, C / Zona, S / Rochira, V et al. | 2008
-
Once-daily regimens were associated with a higher rate of self-chosen discontinuationsMurri, R / Cingolani, A / De Luca, A et al. | 2008
-
Effects of highly active antiretroviral therapy (HAART) on platelet activating factor (PAF) metabolism in HIV-infected patients: in vivo resultsTsoupras, AB / Chini, M / Tsogas, N et al. | 2008
-
Challenges to adherence among HIV-positive patients on antiretroviral therapy in Lagos, NigeriaAdeyemi, AO / Olaogun, OO / Adesola, OA et al. | 2008
-
Activity of etravirine on different HIV-1 subtypes: week 48 data of the pooled DUET trials and in vitro susceptibility in treatment-naïve patientsVingerhoets, J / Azijn, H / Tambuyzer, L et al. | 2008
-
Genotypic susceptibility to tipranavir (TPV) and darunavir (DRV) in a cohort of treatment-experienced patients (TEP)Baxter, J / Bhatti, L / Scherer, J et al. | 2008
-
Quantitation of raltegravir in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of LC-MS/MSter Heine, R / Rosing, H / van Gorp, ECM et al. | 2008
-
Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemiaFabbiani, M / Di Giambenedetto, S / Ragazzoni, E et al. | 2008
-
Determination of HIV-1 co-receptor usage in German patients – comparison of genotypic methods with the $ TROFILE^{®} $ phenotypic assayObermeier, MJ / Berg, T / Sichtig, N et al. | 2008
-
Efficacy and safety of $ Truvada^{®} $in HIV-1 pregnant women: report of 23 casesCiraru-Vigneron, N / Mazeron, MC / Lefevre, V et al. | 2008
-
HIV maternal-fetal transmission in a low resources setting in the outskirts of Buenos Aires, ArgentinaHojman, M / Murano, F / Manonelles, G et al. | 2008
-
A 4-year follow-up of a cohort of HIV-positive cirrhotic patientsTuma, P / Vispo, E / Medrano, J et al. | 2008
-
Differences in CD4 count increases in veterans starting antiretroviral therapy with lopinavir/ritonavir or efavirenzBedimo, RJ / Drechsler, H / Holodniy, M et al. | 2008
-
O124 Efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy?Orrell, C / Cohen, K / Ive, P et al. | 2008
-
Continuing evidence to support the role of early kinetic monitoring in predicting sustained viral response for HIV/HCV co-infected patientsKieran, J / Jackson, A / Shea, DO et al. | 2008
-
Clinical effect of interleukin-2 (IL-2) immuno-adjuvant treatment in HIV+ advanced naïve patientsTincati, C / Cesari, M / Meroni, L et al. | 2008
-
The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patientsDas, S / Arumainayagam, J / Kumari, B et al. | 2008
-
Impact of antiretroviral dosing and daily pill burden on viral rebound rates in naive patients receiving a tenofovir-based regimenAmmassari, A / Lorenzini, P / Maggiolo, F et al. | 2008
-
O113 HIV-1 clade C resistance genotypes after first virological failure in a large community ART programmeOrrell, C / Walensky, RP / Losina, E et al. | 2008
-
CD4+ guided antiretroviral treatment interruption. A meta-analysisDe Silvestri, A / Boschi, A / Tinelli, C et al. | 2008
-
Virological and immunological response to three boosted protease inhibitor regimensBaumgardt, C / Stephan, C / Haberl, AE et al. | 2008
-
Simplification of therapy (ART) with efavirenz/emtricitabine/tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patientsYoung, B / DeJesus, E / Morales-Ramirez, JO et al. | 2008
-
Does HIV-1 tropism change in patients during virological suppressive therapy?Degen, O / Noah, C / Colberg, K et al. | 2008
-
Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavirCanestri, A / Blanc, C / Wirden, M et al. | 2008
-
Efficacy and safety of switching enfuvirtide to raltegravir in patients with viral suppressionSantos, JR / Llibre, JM / Moltó, J et al. | 2008
-
Long-term efficacy of boosted and unboosted atazanavir-containing regimens: results from the SCOLTA ProjectQuirino, T / Ricci, E / Giuntini, R et al. | 2008
-
Anti-inflammatory effect of Omacor during combination antiretroviral therapy: a 12-weeks randomised, double-blind, placebo-controlled trialThusgaard, M / Christensen, JH / Mørn, B et al. | 2008
-
Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment optionsEsser, S / Moll, A / Cairns, V et al. | 2008
-
Hepatic safety of tipranavir/ritonavir (TPV/r)-based antiretroviral therapy: effect of hepatitis virus co-infection and baseline liver fibrosisMacias, J / Orihuela, F / Rivero, A et al. | 2008
-
Lipid changes in patients receiving nevirapine (NVP) in combination with tenofovir/emtricitabine: results from the CCIAT trialDavis, C / Talwani, R / Gilliam, B et al. | 2008
-
Uridine supplementation with Mitocnol attenuates mitochondrial cardiomyopathy induced by zidovudine and zalcitabineBalcarek, K / Lebrecht, D / Deveaud, C et al. | 2008
-
Risk factors and clinical and therapeutic issues of pancreatic abnormalities during HIV infectionManfredi, R / Calza, L et al. | 2008
-
Uridine supplementation with Mitocnol antagonizes antiretroviral nucleoside analogue-induced mitochondrial peripheral and cerebral neuropathy in vivoLebrecht, D / Deveaud, C / Beauvoit, B et al. | 2008
-
Prevalence of cardiovascular risk factors (CRF) and metabolic syndrome (MS) in a cohort of HIV-infected patients in southern Spain. PREGO studyGallego, M / Oñate, F / del Arco, A et al. | 2008
-
A central body fat distribution is related to increased renal arterial resistance index and renal function impairment in HIV-1 infected patientsGrima, PF / Grima, P / Chiavaroli, R et al. | 2008
-
Introduction of a system to screen for chronic kidney disease and monitor for nephrotoxicity of antiretrovirals at an outpatient HIV clinicKelly, S / Bergin, C / Treacy, V et al. | 2008
-
Gender differences in depression evolution in a cohort of patients attending a metabolic clinic for lipodystrophy managementOrlando, G / Squillace, N / Mazeu, I et al. | 2008
-
Screening for liver fibrosis in HIV-mono-infected patients with increased ALT comparing FibroScan with FIB-4Mauss, S / Henke, J / Berger, F et al. | 2008
-
Prevention of mother-to-child transmission of HIV in the HAART era: patterns in use of neonatal prophylaxisEngland, K et al. | 2008
-
HIV lamivudine resistance mutations in HBV co-infected Romanian patientsManolescu, L / Marinescu, P / Sultana, C et al. | 2008
-
HIV-1 pol gene diversity and antiretroviral drug resistance mutations in Itanhaém city, BrazilRodrigues-Matias, RB / Guatelli, KCP / Ambar, RF et al. | 2008
-
Clinical and immuno-virologic outcome in a cohort of immigrant and native subjects with HIV infection in south-eastern Spain during the period 1998–2007Vera-Méndez, FJ / Trujillo-Santos, J / Cano-Sánchez, A et al. | 2008
-
Factors associated with positive tuberculin skin test results in HIV-1 infected Thai patientsTeeratakulpisarn, NT / Phositlimakul, SP / Suwanmala, PS et al. | 2008
-
High rates of viral suppression in HIV/TB patients treated with NNRTI-based antiretroviral therapyCampbell, LJ / Samarawickrama, A / Bailey, AC et al. | 2008
-
Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week resultsClotet, B / Katlama, C / Lazzarin, A et al. | 2008
-
Hepatitis B virus (HBV) genotype distribution and lamivudine-resistant mutations in HIV/HBV co-infected patients attending a Parisian hospitalSchnepf, N / Lafuente-Lafuente, C / Jarrin, I et al. | 2008
-
Pathogenesis of HIV infection: implications for treatment and preventionLane, HC et al. | 2008
-
Results of a Phase I study to evaluate the safety, tolerability, pharmacokinetics (with and without ritonavir) and food-effect of VCH-286Proulx, L / Chauret, N / Clermont, P et al. | 2008
-
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosisNasta, P / Gatti, F / Cologni, G et al. | 2008
-
The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz in antiretroviral-naïve patients through 7 yearsMadruga, JVR / Cassetti, I / Etzel, A et al. | 2008
-
Distribution of autoantibodies and rheumatological manifestations in HIV-positive patients from the University Clinic of Bonn – a pilot studyBecker, EA / Wasmuth, JC / Voigt, E et al. | 2008
-
O114 NNRTI mutations are efficiently transmitted within clusters of new HIV infectionsBrenner, BG / Toni, T d'Aquin / Roger, M et al. | 2008
-
O222 Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trialGibb, DM / Compagnucci, A / Green, H et al. | 2008
-
O214 The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapyCohen, C / Colson, A / Pierone, G et al. | 2008
-
O311 Pathogenesis of non-AIDS morbidities in HIV disease and implications for managementDeeks, S et al. | 2008
-
O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistanceCahn, P / Altclas, J / Martins, M et al. | 2008
-
O415 Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136Delfraissy, JF / Moreno, S / Sanz-Moreno, J et al. | 2008
-
O421 When to start therapy? The patient's viewpointCairns, G / Alcorn, K et al. | 2008
-
Etravirine use in clinical practice: 48-week data from a single centre cohortScott, C / Khatib, N / Bower, M et al. | 2008
-
Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DFViergever, RF / Berg, MJ ten / van Solinge, WW et al. | 2008
-
Efficacy and tolerability of long-term nevirapine plus nucleoside reverse transcriptase inhibitors for HIV-1 infectionCarocci, CA / Martinelli, MC / Mastronardi, MV et al. | 2008
-
Patient characteristics and treatment outcomes associated with protease inhibitor (PI) use in the Asia-Pacific regionPujari, SN / Sungkanuparph, S / Srasuebkul, P et al. | 2008
-
Protease inhibitor atazanavir induces leukocyte-endothelial cell interactions in the microvasculatureAndrade, MM / De Pablo-Bernal, C / Esplugues, JV et al. | 2008
-
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adultsLalezari, J / DeJesus, E / Osiyemi, O et al. | 2008
-
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT studyKlein, CE / Chiu, YL / Da Silva, BA et al. | 2008
-
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitorsWendig, A / Stephan, C / Khaykin, P et al. | 2008
-
Evaluation of adherence and toxicities to HAART in a cohort of HIV+ immigrant patients in south-eastern Spain during the period 1998–2007Vera-Méndez, FJ / Trujillo-Santos, J / Cano-Sánchez, A et al. | 2008
-
PI and OPG/RANKL levels in human osteoblast cellsBorderi, M / Gibellini, D / Tampellini, L et al. | 2008
-
Relationship between different types of non-adherence behaviour and virological response in unselected HIV-positive cohortAmmassari, A / Trotta, MP / Marconi, P et al. | 2008
-
Osteonecrosis in HIV-infected patients treated with HAART: a case control study of predictorsMazzotta, E / Agostinone, A / Sozio, F et al. | 2008
-
Quality of life of HIV-infected individuals in a community-based antiretroviral programmePitt, J / Myer, L / Wood, R et al. | 2008
-
Using the latest resistance score to predict etravirine (ETV) resistance in naïve and NNRTI-failing patientsZaccarelli, M / Lorenzini, P / Ceccherini-Silberstein, CSF et al. | 2008
-
Early predictors of outcome and management of PCP in Glasgow: 11 years experience in the post-antiretroviral eraMackintosh, CL / MacConnachie, A / Nandwani, R et al. | 2008
-
Ten years of non-occupational HIV post-exposure prophylaxis: what have we learned?Tissot, F / Fardel, V / Cavassini, M et al. | 2008
-
Measurement of 3-methylhistidine in spot urine from HIV-infected persons: an alternative screening method for muscle protein degradation to serum CKVenhoff, AC / Bissé, E / Epting, T et al. | 2008
-
Predictors of severe hyperbiliruniaemia in HIV-infected patients treated with atazanavir (ATV)Casana, M / Barassi, A / Cicconi, P et al. | 2008
-
Analysis of HIV variants in blood and semen in serodiscordants by heteroduplex mobility assayJadhav, SK / Velhal, SM / Deshpande, A et al. | 2008
-
Clinical epidemiology of HIV and tuberculosis co-infection in Galati, RomaniaArbune, M / Scorpan, C / Benea, OE et al. | 2008
-
Rituximab and Castleman disease and Kaposi's sarcomaLobo, J / Gallo, C / R-Junquera, M et al. | 2008
-
Factors associated with anxiety, depression and cognitive impairment in elderly patients receiving HAARTLiuzzi, G / Menichetti, S / Libertone, R et al. | 2008
-
Presence of hepatitis B virus in cerebrospinal fluid of HIV-1 co-infected adolescentsDuiculescu, D / Ene, L / Tardei, G et al. | 2008
-
HPV infection in HIV-positive subjects and molecular epidemiologyProtopas, K / Tsiodras, S / Chranioti, K et al. | 2008
-
O212 Rate of change in CD4 counts in patients with stable HIV viremiaPhillips, AN / Ledergerber, B / Bogner, JR et al. | 2008
-
The implications beyond public health if we don't manage the HIV epidemicWhiteside, A et al. | 2008
-
NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluationBrogan, AJ / Everhard, F / Talbird, SE et al. | 2008
-
POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patientsKatlama, C / Bellos, N / Grinsztejn, B et al. | 2008
-
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE studySimpson, KN / Rajagopalan, R / Dietz, B et al. | 2008
-
Economic modeling of the combined effects of HIV disease, heart disease and lipoatrophy based on ACTG 5142 trial dataSimpson, KN / Rajagopalan, R / Dietz, B et al. | 2008
-
Metabolic syndrome among patients initiating HAART and outcome in Southern IndiaSaghayam, S / Kumarasamy, N / Sundaram, M et al. | 2008
-
Factors related to low HDL-cholesterol in HIV-infected patientsPuerta, S / Palacios, R / Orihuela, F et al. | 2008
-
Cardiovascular risk estimation in Spanish HIV-infected patients: a multicenter cohort studyFerrer, E / Minguez, C / Mariño, A et al. | 2008
-
Contribution of antiretroviral therapy, cardiovascular risk factors and constituents of metabolic syndrome to insulin resistance(IR) in HIVJiménez, M Cervero / Perea, R Torres / Aparicio, JL Agud et al. | 2008
-
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on PR interval: results from a thorough QT studyDa Silva, BA / Li, J / Lin, YL et al. | 2008
-
A cross-sectional comparison of serum bone markers in patients on stable abacavir (ABC) or tenofovir (TDF) containing therapyWaters, LJ / Randell, P / Jackson, AGA et al. | 2008
-
Lipid elevations in the ARTEMIS and TITAN trials: effects of demographics, HIV disease stage, treatment arm and lipid-lowering drugsNelson, M / Hill, AM et al. | 2008
-
Subclinical kidney disease in HIV-infected patientsSorlí, ML / Velat, M / Guelar, AM et al. | 2008
-
Traditional risk factors do not predict osteoporosis in HIV patientsChew, NS / McConkey, S / Lambert, J et al. | 2008
-
Therapeutic drug monitoring of new formulation Kaletra in pregnancyJackson, V / Else, LJ / Khoo, SH et al. | 2008
-
Materno-fetal transmission of HIV infection in Constanta county in the last 8 yearsCambrea, SC / Ilie, MM / Marcas, C et al. | 2008
-
Immune restoration during HAART: 8-year follow-up in HIV-positive patients with sustained virological suppressionMalincarne, L / Sgrelli, A / Camanni, G et al. | 2008
-
O134 HIV disease management and challenges in Eastern Europe and Central AsiaBobrik, A et al. | 2008
-
Increased risk for acute HIV infection from non-ulcerative STI's in MSM: aggressive STI eradication programs needed for reduction in HIV incidenceBolan, RK / Tilekar, SD / Clay, E et al. | 2008
-
O422 Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?Waters, LJ / Fisher, M / Anderson, J et al. | 2008
-
O323 High HIV viral load inhibits osteoblast function and signallingChew, NS / Cotter, EJ / Doran, PP et al. | 2008
-
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patternsParaskevis, D / Magiorkinis, E / Magiorkinis, G et al. | 2008
-
Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts)Gatti, F / Matti, A / Nasta, P et al. | 2008
-
Simplification from TPV/RTV 500/200 BID to TPV/RTV 500/100 BID guided by therapeutic drug monitoringMorello, J / Rodríguez-Nóvoa, S / Blanco, F et al. | 2008
-
Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategyEcheverría, P / Domingo, P / Gutierrez, M et al. | 2008
-
A Phase IIIb pilot study substituting darunavir/ritonavir (DRV/r) and etravirine (ETR) for enfuvirtide (ENF) and current PI in a suppressive regimenRuane, P / Alas, B / Ryan, R et al. | 2008
-
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patientsImaz, A / del Saz, S Villar / Rivas, MA et al. | 2008
-
Virologic failure and metabolic syndrome in patients with HIV infectionSquillace, N / Zona, S / Orlando, G et al. | 2008
-
Vitamin D deficiency in the in-patient HIV population: cause or affect?Ancock, B / Bower, M / Gazzard, BG et al. | 2008
-
Mitochondrial impairment in HIV-infected childrenMorén, C / Garrabou, G / Molina, E et al. | 2008
-
Efavirenz induces alterations in lipid metabolism through AMPK activationBlas-García, A / Ballesteros, D / Monleón, D et al. | 2008
-
Frequency of bone abnormalities and associated factors in a Spanish cohort of HIV-infected patientsBonjoch, A / Estany, C / Puig, J et al. | 2008
-
Effect of antiretroviral therapy on homocysteine plasma concentrations in patients with AIDSLopez, H Castro / Ramirez, E Coria / Cisneros, L Nieto et al. | 2008
-
Activation of HIV-specific CD8+ T lymphocytes by histamine depends also on the total NK cellsSedláèek, D / Hanzlíková, J / Liška, M et al. | 2008
-
Adherence to antiretroviral therapies in people with HIV infection: a qualitative approach from a narrative-based medicine studyTomasini, A / Murri, R / Guaraldi, G et al. | 2008
-
Progression to AIDS in HIV vertically infected children diagnosed and ARV treated from first year of lifeDobosz, S / Marczyñska, M / Oldakowska, A et al. | 2008
-
Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected with Clade C virusEng, S / Sanne, I / Badal-Faesen, S et al. | 2008
-
Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancyPeña, JM / González, MI / Pascual-Pareja, JF et al. | 2008
-
Outcome of pregnancies in HIV-positive women followed up at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, between 1997 and 2007Kint, I / Pelgrom, J / Maes, P et al. | 2008
-
Particular aspects of mother-to-child transmission of HIV infection: single center's 7-year experience in RomaniaOprea, C / Ungureanu, E / Radoi, R et al. | 2008
-
Ezetimibe as lipid-lowering therapy for patients receiving HAARTAsghar, AK / Bower, M / Holmes, P et al. | 2008
-
Effect of hemolysis on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a 2-year analysisPattery, T / Bovee, I / Rousseau, E et al. | 2008
-
Rapid virological response is the best predictor for achieving SVR under peg-IFN/ribavirin hepatitis C therapy in HIV/HCV co-infected patientsJanke, M / Luechters, G / Vogel, M et al. | 2008
-
Retrospective evaluation of cases of CNS toxoplasmosis in patients with AIDS hospitalized in the Department of Hospital for Infectious Diseases, WarsawMiarka, MA / Gizinska, J / Latarska-Smuga, D et al. | 2008
-
Non-nucleoside-based antiretroviral regimens are most durable and cost-effective as first treatments in an urban setting from a developing countryBissio, E / Lopardo, GD et al. | 2008
-
O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UKChilton, D / Harrison, L / Green, H et al. | 2008
-
O211 HIV and the brain: neuro-inflammation long-term, CNS control of HIV replication, brain disease in suppressed patients and differential penetration of drugsClifford, D et al. | 2008
-
Outcome of chronic hepatitis delta in patients with and without HIV infection in the HAART eraTuma, P / Vispo, E / Barreiro, P et al. | 2008
-
A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adultsMahungu, TW / Else, LJ / Smith, CJ et al. | 2008
-
96 weeks pharmacoeconomic outcome of lopinavir/r monotherapy as maintenance strategy in HIV+ patients with suppressed viral load. OK04-PharmECO analysisArribas, JR / Pulido, F / Méndez, I et al. | 2008
-
Antiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow CohortStephan, C / Jaeger, H / Carganico, A et al. | 2008
-
An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UKElbasha, E / Dunlop, W / Chaudhary, MA et al. | 2008
-
Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week resultsHaubrich, R / Eron, J / Thompson, M et al. | 2008
-
O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) – myocardial infarction and abacavir useKowalska, JD / Kirk, O / Mocroft, A et al. | 2008
-
Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppressionByakwaga, H / Murray, JM / Petoumenos, K et al. | 2008
-
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosingBrandolini, M / Cattelan, A / Orani, A et al. | 2008
-
Abacavir and cardiovascular risk in HIV-infected patients: does T-lymphocyte hyperactivation exert a pathogenic role?Casana, M / Bellistrì, GM / Tincati, C et al. | 2008
-
Use of traditional complementary and alternative medicine (TCAM) by HIV patients prior to initiating ART in KwaZulu-Natal, South AfricaPeltzer, K / Preez, N Friend-du / Ramlagan, S et al. | 2008
-
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in VietnamNhung, VT Tuyet / Colby, D / Thuy, H Thu et al. | 2008
-
Protease inhibitor-induced cardiotoxicity: direct effects on cell viability and intracellular calcium levelsSpiers, JP / Edwards, C / Rietz, A et al. | 2008
-
Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION studyAbdon, A / Cosín, J / Pasquau, J et al. | 2008
-
Body physical changes in HIV patients under antiretroviral treatment in SpainGriffa, L / Cabrero, E / Burgos, A et al. | 2008
-
Impact of fasting bloods on hypertriglyceridemiaBilling, NA / Moyle, GJ / Nelson, M et al. | 2008
-
Experience of myocardial infarction in a Glasgow HIV cohortEnglish, S / Winter, A / Nandwani, R et al. | 2008
-
Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN trialCalvez, V / Hill, AM / Marcelin, AG et al. | 2008
-
Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western IndiaPujari, SN / Dravid, AN / Gupte, N et al. | 2008
-
HIV treatment decision making: high rate of revised treatment choices based upon different genotypic interpretation systemsWolf, E / Gersbacher, E / Vogel, M et al. | 2008
-
Continuous decline in prevalence of drug resistance mutations among naïve and cART experienced HIV-positive patients in Poland over timeStanczak, GP / Przybylska-Stengiel, KJ / Firlag-Burkacka, E et al. | 2008
-
Incidence of immune reconstitution inflammatory syndrome among HIV patients infected with tuberculosis in a Dublin cohortMuldoon, EG / Mokoka, M / Kok, P et al. | 2008
-
Occupational HIV exposure among Thai healthcare workers: an analysis of 558 exposures during 1998–2007Wangpatharawanit, P / Padiwongpaisarn, W / Phanuphak, N et al. | 2008
-
Plasma concentrations of boosted and unboosted atazanavir are predicted by 63396C>T SNP in the PXR geneSiccardi, M / D'Avolio, A / Baietto, L et al. | 2008
-
Antivirals and nuclear receptor activation of CYP3A4 and 2B6Svard, J / Spiers, JP / Mulcahy, F et al. | 2008
-
Impact of HIV treatment on clearance of human papillomavirus (HPV) infection in HIV-infected womenKonopnicki, D / Manigart, Y / Scheen, R et al. | 2008
-
O133 HIV/TB: when is it safe to start HAART?Wood, R et al. | 2008
-
What about primary pulmonary hypertension in HIV infection in the era of combination antiretroviral therapy?Mary-Krause, M / Lascoux-Combe, C / Simon, A et al. | 2008
-
Thrombopenia and/or splenomegaly in HIV/HCV co-infected patients with mild liver fibrosis alerts for the risk of portal hepatopathyVispo, E / Maida, I / Barreiro, P et al. | 2008
-
Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patientsBánhegyi, D / Katlama, C / Da Cunha, C et al. | 2008
-
O123 To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS)Walker, AS / Boyd, KL / Doerholt, K et al. | 2008